These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 17545532)

  • 41. 31P NMR spectroscopy and polarographic combined study of erythrocytes treated with 5-fluorouracil: cardiotoxicity-related changes in ATP, 2,3-BPG, and O2 metabolism.
    Spasojević I; Zakrzewska J; Bacić GG
    Ann N Y Acad Sci; 2005 Jun; 1048():311-20. PubMed ID: 16154943
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Impact of cancer muscle mass loss on anticancer treatment toxicities].
    Chemama S; Raynard B; Antoun S
    Bull Cancer; 2016 Sep; 103(9):786-93. PubMed ID: 27206822
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review of body composition and pharmacokinetics in oncology.
    Hopkins JJ; Sawyer MB
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):947-956. PubMed ID: 28649898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Body composition and chemotherapy toxicity among women treated for breast cancer: a systematic review.
    Wopat H; Harrod T; Brem RF; Kaltman R; Anderson K; Robien K
    J Cancer Surviv; 2024 Aug; 18(4):1356-1369. PubMed ID: 37093518
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Getting the right dose in cancer chemotherapy--time to stop using surface area?
    Newell DR
    Br J Cancer; 2002 Apr; 86(8):1207-8. PubMed ID: 11953873
    [No Abstract]   [Full Text] [Related]  

  • 46. Body surface area capping may not improve cytotoxic drugs tolerance.
    Bouleftour W; Viard A; Mery B; Chaux R; Magne N; Simoens X; Rivoirard R; Forges F
    Sci Rep; 2021 Jan; 11(1):2431. PubMed ID: 33510207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Corrigendum to "5-Fluorouracil-induced toxicity in both male and female reproductive systems: A narrative review".
    Hum Exp Toxicol; 2023; 42():9603271231224521. PubMed ID: 38147029
    [No Abstract]   [Full Text] [Related]  

  • 48. [Arsenobenzenes, their composition, their toxicity; an update].
    DE MYTTENAERE F
    J Pharm Belg; 1947; 2(9-10):214-8. PubMed ID: 18901844
    [No Abstract]   [Full Text] [Related]  

  • 49. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
    Prado CM; Baracos VE; McCargar LJ; Reiman T; Mourtzakis M; Tonkin K; Mackey JR; Koski S; Pituskin E; Sawyer MB
    Clin Cancer Res; 2009 Apr; 15(8):2920-6. PubMed ID: 19351764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.
    Prado CM; Lieffers JR; McCargar LJ; Reiman T; Sawyer MB; Martin L; Baracos VE
    Lancet Oncol; 2008 Jul; 9(7):629-35. PubMed ID: 18539529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Definition and classification of cancer cachexia: an international consensus.
    Fearon K; Strasser F; Anker SD; Bosaeus I; Bruera E; Fainsinger RL; Jatoi A; Loprinzi C; MacDonald N; Mantovani G; Davis M; Muscaritoli M; Ottery F; Radbruch L; Ravasco P; Walsh D; Wilcock A; Kaasa S; Baracos VE
    Lancet Oncol; 2011 May; 12(5):489-95. PubMed ID: 21296615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care.
    Mourtzakis M; Prado CM; Lieffers JR; Reiman T; McCargar LJ; Baracos VE
    Appl Physiol Nutr Metab; 2008 Oct; 33(5):997-1006. PubMed ID: 18923576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.
    Martin L; Birdsell L; Macdonald N; Reiman T; Clandinin MT; McCargar LJ; Murphy R; Ghosh S; Sawyer MB; Baracos VE
    J Clin Oncol; 2013 Apr; 31(12):1539-47. PubMed ID: 23530101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.
    Ali R; Baracos VE; Sawyer MB; Bianchi L; Roberts S; Assenat E; Mollevi C; Senesse P
    Cancer Med; 2016 Apr; 5(4):607-16. PubMed ID: 26814378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.
    Cruz-Jentoft AJ; Baeyens JP; Bauer JM; Boirie Y; Cederholm T; Landi F; Martin FC; Michel JP; Rolland Y; Schneider SM; Topinková E; Vandewoude M; Zamboni M;
    Age Ageing; 2010 Jul; 39(4):412-23. PubMed ID: 20392703
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer.
    Barret M; Antoun S; Dalban C; Malka D; Mansourbakht T; Zaanan A; Latko E; Taieb J
    Nutr Cancer; 2014; 66(4):583-9. PubMed ID: 24707897
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.
    Cespedes Feliciano EM; Lee VS; Prado CM; Meyerhardt JA; Alexeeff S; Kroenke CH; Xiao J; Castillo AL; Caan BJ
    Cancer; 2017 Dec; 123(24):4868-4877. PubMed ID: 28881381
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer.
    Tan BH; Birdsell LA; Martin L; Baracos VE; Fearon KC
    Clin Cancer Res; 2009 Nov; 15(22):6973-9. PubMed ID: 19887488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Body composition in chemotherapy: the promising role of CT scans.
    Prado CM
    Curr Opin Clin Nutr Metab Care; 2013 Sep; 16(5):525-33. PubMed ID: 23799328
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
    Antoun S; Baracos VE; Birdsell L; Escudier B; Sawyer MB
    Ann Oncol; 2010 Aug; 21(8):1594-1598. PubMed ID: 20089558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.